TRS Publications

2021

Identification, Characterization, and Suppression of Side Products Formed during the Synthesis of [177Lu]Lu-PSMA-617.

Martin S, Tönnesmann R, Hierlmeier I, Maus S, Rosar F, Ruf J, Holland JP, Ezziddin S, Bartholomä MD

J Med Chem. 2021 Apr 7

Novel Peptide-Based PET Probe for Non-invasive Imaging of C-X-C Chemokine Receptor Type 4 (CXCR4) in Tumors.

Trotta AM, Aurilio M, D'Alterio C, Ieranò C, Di Martino D, Barbieri A, Luciano A, Gaballo P, Santagata S, Portella L, Tomassi S, Marinelli L, Sementa D, Novellino E, Lastoria S, Scala S, Schottelius M, Di Maro S

J Med Chem. 2021 Mar 25;64(6):3449-3461

Proof-of-Concept Study of the NOTI Chelating Platform: Preclinical Evaluation of 64Cu-Labeled Mono- and Trimeric c(RGDfK) Conjugates.

Martin S, Maus S, Stemler T, Rosar F, Khreish F, Holland JP, Ezziddin S, Bartholomä MD

Mol Imaging Biol. 2021 Feb;23(1):95-108

2020

At the bench: Pre-clinical evidence for multiple functions of CXCR4 in cancer.

Luker GD, Yang J, Richmond A, Scala S, Festuccia C, Schottelius M, Wester HJ, Zimmermann J

J Leukoc Biol. 2020 Oct 26

A new class of PentixaFor- and PentixaTher-based theranostic agents with enhanced CXCR4-targeting efficiency.

Osl T, Schmidt A, Schwaiger M, Schottelius M, Wester HJ

Theranostics. 2020;10(18):8264-8280

[99cmTc]Tc-PSMA-I&S-SPECT/CT: experience in prostate cancer imaging in an outpatient center

P. Werner, C. Neumann, M. Eiber, H. J. Wester & M. Schottelius

EJNMMI Research. 2020 May; Volume 10, Article number: 45

From Theranostics to Immunotheranostics: the Concept

Niklaus Schaefer, John O. Prior & Margret Schottelius

54, pages 81–85(2020)

"Luke! Luke! Don't! It's a trap!"-spotlight on bias in animal experiments in nuclear oncology.

Nonnekens J, Schottelius M

Eur J Nucl Med Mol Imaging. 2020 May;47(5):1024-1026

Dernière mise à jour le 05/05/2020 à 11:26